KIM
TEVA icon

Kestra Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Kestra Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31
Closed -$683 – 1364
2024
Q4 		$683 Buy
+31
New +$564 ﹤0.01% 1120

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Kestra Investment Management's TEVA Position: Q1 2025 in Review

Kestra Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 31 shares — an estimated $683 sold.

Kestra Investment Management first reported a position in TEVA in Q4 2024 and held it in 1 quarter. The position peaked at $683 in Q4 2024. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Kestra Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Kestra Investment Management sold 31 Teva Pharmaceuticals shares in Q1 2025, an estimated $683.
  • Kestra Investment Management first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Kestra Investment Management's Teva Pharmaceuticals position peaked at $683 in Q4 2024.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Kestra Investment Management's 13F filing for Q1 2025, filed 16 May 2025.